Japan Dose Regimen Study of AZD1656 in Japanese Type 2 Diabetes Mellitus Patients
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 224 participants.
Also called NCT01152385
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 224 participants
- Sponsor
- Registry
-
NCT01152385
-
- Other papers using this trial's data
- Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT01152385. Randomized; double masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2011-05 (actual). Results posted on 2012-08-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Japan Dose Regimen Study of AZD1656 in Japanese Type 2 Diabetes Mellitus Patients
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- AZD1656
- Intervention (Drug)
- Placebo
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct01152385- Content hash
b9eb9d6188bdb8a52ac5500948a2ee28b1bacac5f45fb88f209e39425a8853e1